336 related articles for article (PubMed ID: 34351555)
1. Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07.
Kakeji Y; Yoshida K; Kodera Y; Kochi M; Sano T; Ichikawa W; Lee SW; Shibahara K; Shikano T; Kataoka M; Ishiguro A; Ojima H; Sakai Y; Musha N; Takase T; Kimura T; Takeuchi M; Fujii M
Gastric Cancer; 2022 Jan; 25(1):188-196. PubMed ID: 34351555
[TBL] [Abstract][Full Text] [Related]
2. Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study.
Kodera Y; Yoshida K; Kochi M; Sano T; Ichikawa W; Kakeji Y; Sunakawa Y; Takeuchi M; Fujii M
Gastric Cancer; 2023 Nov; 26(6):1063-1068. PubMed ID: 37548812
[TBL] [Abstract][Full Text] [Related]
3. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.
Sasako M; Sakuramoto S; Katai H; Kinoshita T; Furukawa H; Yamaguchi T; Nashimoto A; Fujii M; Nakajima T; Ohashi Y
J Clin Oncol; 2011 Nov; 29(33):4387-93. PubMed ID: 22010012
[TBL] [Abstract][Full Text] [Related]
4. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial.
Yoshida K; Kodera Y; Kochi M; Ichikawa W; Kakeji Y; Sano T; Nagao N; Takahashi M; Takagane A; Watanabe T; Kaji M; Okitsu H; Nomura T; Matsui T; Yoshikawa T; Matsuyama J; Yamada M; Ito S; Takeuchi M; Fujii M
J Clin Oncol; 2019 May; 37(15):1296-1304. PubMed ID: 30925125
[TBL] [Abstract][Full Text] [Related]
5. Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy.
Fujitani K; Tamura S; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Shimokawa T; Tsujinaka T; Furukawa H
Gastric Cancer; 2014 Apr; 17(2):348-53. PubMed ID: 23736741
[TBL] [Abstract][Full Text] [Related]
6. Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002).
Fujitani K; Tamura S; Kimura Y; Matsuyama J; Imamura H; Yamamoto K; Fujita J; Iijima S; Ueda S; Kurokawa Y; Shimokawa T; Satoh T;
Gastric Cancer; 2020 May; 23(3):520-530. PubMed ID: 31667688
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study.
Endo S; Terazawa T; Goto M; Tanaka R; Kato T; Fujitani K; Kawakami H; Sakai D; Kurokawa Y; Tsujinaka T; Shimokawa T; Satoh T
BMC Cancer; 2022 Jul; 22(1):811. PubMed ID: 35870893
[TBL] [Abstract][Full Text] [Related]
9. Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials.
Kimura Y; Kawakami H; Tamura S; Fujitani K; Matsuyama J; Imamura H; Iijima S; Sakai D; Kurokawa Y; Shimokawa T; Tsujinaka T; Furukawa H; Satoh T
Gastric Cancer; 2023 Sep; 26(5):788-797. PubMed ID: 37335367
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
[TBL] [Abstract][Full Text] [Related]
12. Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S - 1 therapy.
Yamaguchi T; Kawakami H; Sakai D; Kurokawa Y; Shimokawa T; Goto M; Satoh T
BMC Cancer; 2022 Jul; 22(1):773. PubMed ID: 35840917
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.
Kosaka T; Akiyama H; Miyamoto H; Sato S; Tanaka Y; Sato K; Kunisaki C; Endo I
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1047-1055. PubMed ID: 30911769
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB-IV gastric cancer.
Yoon S; Yoo C; Ryu MH; Kang MJ; Ryoo BY; Park SR; Yook JH; Oh ST; Yoo MW; Kim BS; Kang YK
Gastric Cancer; 2017 Jan; 20(1):182-189. PubMed ID: 26661592
[TBL] [Abstract][Full Text] [Related]
15. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
16. Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy.
Tamura S; Fujitani K; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Furukawa H;
Oncology; 2011; 80(5-6):296-300. PubMed ID: 21778769
[TBL] [Abstract][Full Text] [Related]
17. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.
Fujitani K; Yang HK; Mizusawa J; Kim YW; Terashima M; Han SU; Iwasaki Y; Hyung WJ; Takagane A; Park DJ; Yoshikawa T; Hahn S; Nakamura K; Park CH; Kurokawa Y; Bang YJ; Park BJ; Sasako M; Tsujinaka T;
Lancet Oncol; 2016 Mar; 17(3):309-318. PubMed ID: 26822397
[TBL] [Abstract][Full Text] [Related]
18. Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol.
Namikawa T; Maeda H; Kitagawa H; Oba K; Tsuji A; Yoshikawa T; Kobayashi M; Hanazaki K
BMC Cancer; 2018 Feb; 18(1):186. PubMed ID: 29439671
[TBL] [Abstract][Full Text] [Related]
19. 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer.
Yoshikawa T; Terashima M; Mizusawa J; Nunobe S; Nishida Y; Yamada T; Kaji M; Nomura T; Hato S; Choda Y; Yabusaki H; Yoshida K; Misawa K; Masuzawa T; Tsuda M; Kawachi Y; Katayama H; Fukuda H; Kurokawa Y; Boku N; Sano T; Sasako M
Gastric Cancer; 2024 Jan; 27(1):155-163. PubMed ID: 37989806
[TBL] [Abstract][Full Text] [Related]
20. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
